Perrigo Company reported a 3.2% decline in second-quarter net sales to $1.02 billion, impacted by category softness and macroeconomic challenges, but achieved market share growth in U.S. store-brand OTC and key European brands. The company completed the sale of its Dermacosmetics business and is reviewing its Infant Formula and Oral Care segments as part of its strategic portfolio streamlining. Despite short-term pressures, Perrigo reaffirmed its full-year 2026 outlook, expecting stronger second-half performance supported by operational improvements and market share gains. The company continues to focus on debt reduction, operational efficiency, and long-term shareholder value creation amid an uncertain economic environment.
EURR, a new euro-backed stablecoin launched by Bridge Building S.A., gained $665,300 in market cap within 24 hours shortly after its August 26, 2026 launch. Backed 1:1 by euros held in regulated banks and compliant with the EU's MiCA regulations, EUR...
Tokenized equity trading volume reached nearly $3 billion weekly in August, driven mainly by Robinhood Chain, BNB Chain, and Solana. Despite this growth, only about 5% of tokenized stocks are used in onchain financial applications, with total value l...
Ethereum is set to upgrade its network with EIP-8141, introducing 'frame transactions' that split one transaction into up to 64 programmable frames. This new transaction type enables native account abstraction, gas sponsorship, and atomic batching, a...
As of June 30, 2026, thirty institutional investors collectively held about $74.9 million in Hyperliquid ETF products, with Brazil's Wealth High Governance Asset Management leading at nearly $24 million in the 21Shares' THYP fund. These ETFs track th...
Useless Coin (USELESS) hit a 10-month high of $0.286 after rallying 300% in a week, driven by strong buying and new holders. Despite intense buying pressure and positive momentum indicators, the rally may be overextended, suggesting a potential pullb...
